RAINBOW
Kita
About RAINBOW
With the goals of high quality, efficacy, safety, and economic efficiency, RAINBOW is developing HUNS001, a proprietary autologous bone marrow mesenchymal stem cell product that is administered directly to the peri-stroke area. RAINBOW is focused on HUNS001's efficacy, safety, and highly novel cell culture, transport, and administration methods.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $1.4M
- Funding stage: Seed
- Last round: Seed (Oct 2020)
- Website: rainbowinc.co.jp
- Phone: [email protected]
Industries & Categories
Health Care, Manufacturing, Medical
Social Profiles
Canonical: https://fsome.com/organization/rainbow-169170 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.